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Sumário 
A Leucemia Linfoblástica Aguda (LLA) é o tumor pediátrico mais comum. Trata-se de 
uma doença genética complexa que resulta numa proliferação anormal e não controlada 
de precursores linfóides que impedem a diferenciação linfóide normal. Os progressos a 
nível do tratamento, devido ao avanço do conhecimento molecular da doença, levaram a 
uma taxa de sobrevivência de 5 anos superior a 85% nos países desenvolvidos. Contudo, 
a recidiva e a resistência à terapia ainda permanecem um desafio. Desta forma, a 
identificação de novas estratégias terapêuticas é necessária para não só para aumentar a 
sobrevida global mas também para diminuir a taxa de recidiva desta doença. 
A proteína ancorada de superfície glycosylphosphatidylinositol Vanin-2, também 
conhecida como VNN2 e GPI-80, tem sido implicada na adesão e migração leucocitária 
e, mais recentemente, na função das células stem hematopoiéticas fetais. Anteriormente, 
o nosso grupo identificou a sobre-expressão da proteína VNN2 em doentes com risco 
muito elevado de recidiva bem como em doentes portadores do rearranjo TCF3-HLF 
resultante da translocação t(17;19)(q21-q22;p13), um subtipo raro de LLA associado a 
um mau prognóstico. Com o objetivo de explorar a relevância de VNN2 como um 
biomarcador, o nosso grupo demonstrou que a deteção de VNN2 na superfície 
membranar está associada com recidiva num estudo de coorte retrospetivo de doentes 
tratados com o mesmo protocolo clínico internacional. Para além disso, a VNN2 foi 
sempre detetada nos casos positivos para o rearranjo TCF3-HLF, o que parece justificar 
a inclusão prospetiva deste marcador na imunofenotipagem da LLA. 
Para explorar a função da VNN2, nós estabelecemos uma abordagem de deleção da 
VNN2 através da libertação de um sistema lentiviral de CRISPR-CAS9 em células de 
LLA. Com este trabalho, demonstramos que uma redução eficiente da expressão desta 
proteína é atingida na superfície celular, o que fornece um sistema para futura validação 
funcional. No sentido de estabelecer um protocolo para deteção de VNN2 por citometria 
de fluxo procedemos à comparação e validação de dois anticorpos monoclonais, 
fornecendo as ferramentas necessárias para uma avaliação prospetiva da VNN2 como 
um biomarcador num estudo clínico cooperativo em curso. Para concluir, a descoberta da 
expressão aumentada da proteína VNN2 como um candidato a marcador de mau 
prognóstico na LLA pode contribuir para a melhor identificação da doença agressiva na 
LLA. O esforço desenvolvido nesta dissertação de mestrado irá contribuir para a 
avaliação tanto funcional como clínica da VNN2 na LLA. 
Palavras-chave: Leucemia Linfoblástica Aguda, TCF3-HLF, recidiva, VNN2, anticorpo, 
CRISPR/CAS9. 
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Summary 
Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. ALL is 
a complex genetic disease that results in abnormal, uncontrolled proliferation of lymphoid 
precursors blocking normal lymphoid differentiation. The development of treatment due to 
molecular understanding improvement of the disease has led to a 5-year survival rate of 
more than 85% in developed countries. However, relapse and therapy-resistance still 
remain a challenge. Identification of novel therapeutic strategies is required to improve the 
outcome of refractory and relapsed ALL. 
The glycosylphosphatidylinositol anchored surface protein Vanin-2, also known as 
VNN2 and GPI-80, has been implicated in leukocyte adherence and migration and most 
recently in fetal hematopoietic stem cell function. Previously, our group identified VNN2 as 
a unique feature in patients with very high risk of relapse by minimal residual disease as 
well as high surface levels in translocation t(17;19) (TCF3-HLF) positive patients, a rare 
subtype with a very poor outcome. To explore the relevance of VNN2 as a biomarker, we 
showed that detection of VNN2 at the surface of ALL was associated with relapse in a 
retrospective cohort of patients that were treated on the same international clinical 
protocol. Moreover, we found VNN2 to be always detected in TCF3-HLF ALL, which 
justifies prospective inclusion of the marker in ALL immunophenotyping.  
To explore the function of VNN2, we have established a VNN2 deletion approach by 
lentiviral delivery of CRISPR/CAS9 in ALL cells. We show that very efficient reduction of 
VNN2 expression in cell surface is achieved, which provides a system for further 
functional validation. We also contributed to standardize the protocol for detection of 
VNN2 by flow cytometry, comparing two monoclonal antibodies and validating them for 
this application. This provides tools for prospective evaluation of VNN2 as a biomarker in 
the setting of an ongoing cooperative clinical study. Taken together, the discovery of 
VNN2 as a candidate marker of worse outcome in ALL uncovers a so far unrecognized 
feature that is associated with aggressive disease in ALL. The endeavor developed in this 
Master Thesis will contribute to both functional and clinical evaluation of VNN2 in ALL.  
Key-words: Acute Lymphoblastic Leukemia, relapse, VNN2, TCF3-HLF positive ALL, 
VNN2 antibody, CRISPR/Cas9 technique. 
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Abbreviation List 
ALL – Acute Lymphoblastic Leukemia; 
Cas9 – CRISPR associated protein 9; 
cDNA – complementary DNA; 
CNS – Central Nervous System; 
CRISPR – Clustered Regularly 
Interspaced Short Palindromic Repeats; 
DOX – Doxycycline; 
FACS – Fluorescence-Activated Cell 
Sorting; 
FMO – Fluorescence Minus One; 
GFP – Green Fluorescent Protein; 
HR – High risk of relapse; 
HSC – Hematopoietic Stem Cell; 
IR – Intermediate risk of relapse; 
ITGAM – Integrin alpha M, also known 
as Mac-1; 
LLA – Leucemia Linfoblástica Aguda; 
MFI – Mean Flourescence Intensity; 
MRD – Minimal Residual Disease; 
NGS – NOD/SCID/IL2rγnull mouse; 
PE – Phycoerythrin;  
sgRNA – single guide RNA; 
SR – Standard risk of relapse; 
TCF3-HLF – fusion gene   
 t(17;19)(q21-q22;p13); 
TCF3-PBX1 – fusion gene 
t(1;19)(q23;p13); 
VHR – Very high risk of relapse; 
VNN2 – Human glycosylphosphatidyl- 
inositol anchored cell-surface protein; 
also known as Vanin-2 or GPI-80.
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1. Introduction 
1.1 Acute Lymphoblastic Leukemia 
Leukemia, from Greek leukós (“white”) and haĩma (“blood”), is a malignant disorder of 
the hematopoietic system characterized by uncontrolled, neoplastic proliferation of 
leukocytes and their precursors. Leukemia can be classified as acute or chronic: whereas 
the acute form progresses very fast and is more common in children, the chronic one 
tends to grow slower and is typically present in adults. In another hand, it is possible to 
classify it between myeloid or lymphoblastic depending on the origin of the disease and 
the type of leukocytes affected. In this way, leukemia is divided in four common types: 
acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocitic 
leukemia (CLL) and chronic myeloid leukemia (CML).1 The present thesis will focus on 
pediatric acute lymphoblastic leukemia. 
1.1.1 Epidemiology 
In the north part of Portugal, between 1997 and 2006, leukemia was the first common 
cancer identified in childhood (27%) followed by tumors of the central nervous system 
(CNS; 22%) and lymphomas (14%).2 In 2012, leukemia still was the top one pediatric 
cancer in Portugal and worldwide.3 Steady progress in development of effective 
treatments has led to a 5-year survival rate of more than 85% in developed countries4, 5. 
However, 25% of pediatric ALL patients still relapse.5, 6 The precise assessment of the risk 
of relapse in individual patients is essential to ensure an intensive treatment primarily 
limited to high-risk cases and preventing the low-risk cases from unnecessary toxicities. 
To increase the survival rate and the quality of patients‟ life is also required a better 
understanding of ALL pathobiology and the mechanisms of resistance for the 
development of new promising therapeutic strategies.4, 6  
1.1.2 Pathogenesis 
ALL is a genetic disorder malignancy of lymphoid progenitor cells which are supposed 
to differentiate into functional T or B-cells. These genetic disorders include mutations that 
lead to developmental arrest and unlimited self-renew.7 The initial genetic lesions usually 
could be observed in utero and it requires additional submicroscopic genetic alterations to 
give rise to a full leukemia.8  
In most of the cases, genetic lesions of diagnosis and relapse are different (Figure 1). 
Relapse often arises from the emergence of a minor subclone with genetic alterations 
distinct from those of the predominant clone at diagnosis. Since normally the relapse 
clone is present in low proportions at diagnosis and shares some lesions with the 
predominant one, these genetic alterations seem to confer resistance to the treatment.8 
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Thus, it is important to identify which exposures and inherited genetic variants are relevant 
and how and when they play a role in the complex multistep development of the acute 
lymphoblastic leukemia.  
 
 
 
 
Figure 1 – Development of B lymphoblastic leukemia. The genetic alterations that 
contribute to leukemogenesis and the difference between diagnosis and relapse (adapted from 
Inaba et al, 2013 
8
). 
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1.1.3 Diagnosis  
Patients suffering from ALL usually show common symptoms as general fatigue, 
fever, infections, unusual bruising, bone pain and enlarged lymph nodes, liver and spleen 
as a result of the impaired hematopoiesis in the bone marrow, lymphoid organs and 
extramedullary sites.9 
For diagnosis, a bone marrow aspiration is always performed for multiple analyses. 
On one hand, leukemic lymphoblasts are examined by microscopy to see their 
morphology and identify the phenotype of leukemia. Moreover, flow cytometry is 
performed to measure the expression of specific leukemia-associated surface markers 
and, consequently, classify the lineage developmental and maturation stage based on the 
T-cell, mature B-cell and B-cell precursor phenotypes.7 On the other hand, the genotype 
of the leukemia is assessed by chromosomal analysis, RT-PCR, fluorescence in-situ 
hybridization and flow cytometry thus leading to the identification of specific 
translocations, gain or loss of cellular DNA content and submicroscopic chromosomal 
abnormalities with prognostic or therapeutic relevance.7, 8  
1.1.4 Treatment 
The treatment for ALL typically consists of three different phases: remission-induction 
phase, intensification (consolidation) phase and continuation therapy.7, 8 It normally takes 
2 years and the dosages and schedule of chemotherapy are determined based on 
leukemic-cell biological features, response to treatment and pharmacodynamic and 
pharmacogenomic features of patients.8  
The remission-induction phase (4-6 weeks) aims to eradicate the initial leukemic cell 
burden and to restore the normal hematopoiesis. The chemotherapy typically includes 
vincristine, a glucocorticoid (prednisone or dexamethasone) and a third drug 
(asparaginase, anthracycline or both). For standard-risk cases, after given an intensified 
post-remission treatment, this three-drug combination is sufficient to maintain the 
remission for most of the cases. However, for high-risk or very high-risk cases of ALL, 
additional drugs are needed. In pediatric ALL, clinical remission is achieved in 96-98% of 
the cases after this first phase of treatment.7, 8 
After the remission-induction phase, normal hematopoiesis and body function are 
restored. Then, intensification (consolidation) therapy is given in order to eradicate drug-
resistant residual leukemic cells and consequently the risk of relapse.7 During this phase 
(2-4 months), methotrexate at high-dose in association with mercaptopurine is often 
administered as well as pulses of vincristine, glucocorticoids, uninterrupted asparaginase 
(during 20-30 weeks). Re-induction therapy can also be given when therapeutic fail occurs 
and drugs similar to those used in the first phase are administered.7, 8 In addition, most of 
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the children with leukemia have subclinical CNS involvement at the time of diagnosis. 
Since leukemic cells are protected from systemic chemotherapy due to the blood brain 
barrier, which lead to 30-40% of the patients to relapse, CNS-directed therapy is a crucial 
requirement for successful ALL treatment.1, 7 
Finally, in the last phase (continuation therapy) patients receive daily mercaptopurine 
and weekly methotrexate in two years or longer in order to maintain remission and prevent 
relapse. Dosage of the drugs is regularly adjusted according to the patient‟s leukocyte and 
neutrophil count.7, 8 
For very high risk (VHR) patients or patients with poor initial response, allogenic 
hematopoietic stem-cell transplantation is required. In that case, the levels of disease 
burden should be reduced before transplantation. However, leukemia free survival is not 
dependent on the source of stem cells (matched related, matched unrelated, cord blood or 
haploidentical donor) but correlate with the minimal residual disease (MRD):  high MRD 
levels are negatively associated with survival. However, even in patients that do not reach 
negative MRD, the ones that present low MRD levels (0,01-5%) can still benefit from the 
transplantation.10 
The development and refinement of treatments have led to high cure rates of 
pediatric ALL of around 85%. Nevertheless, new treatments are still urgently needed for 
relapse cases. Besides, the effects to reduce the toxicity of chemotherapy are another 
research hot point. Identification of better prognostic markers and profiling with the 
employment of cutting-edge technologies, including next-generation genome sequencing 
and high-throughput drug screen, provides promising progresses of personalized 
treatments with more potent effect and less side effects.4 
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1.2 Prognostic factors in acute lymphoblastic leukemia 
Careful risk stratification is essential to adjust chemotherapeutic treatment and to 
increase the patient survival rate. Clinical factors, genetic aberrations and treatment 
response are evaluated in order to estimate the prognosis (Table 1).  
1.2.1 Clinical factors 
The clinically relevant prognostic factors include age, leukocyte count, sex and 
immunophenotype. Children aged 1-9 have a better outcome than infants or adolescents, 
thus presenting a higher survival probability. Leucocyte count equal or higher than 50 x 
109/L as well as male sex and T-cell immunophenotype are adverse factors that confer 
poor outcome.8 
1.2.2 Biological factors – molecular genetics of ALL 
Around 75% of pediatric ALL cases harbor one or more gross chromosomal 
alterations (Figure 2) and therefore cytogenetic characterization is commonly performed at 
diagnosis. However, only some genetic alterations are clinically validated as strong 
prognostic factors. Favorable outcome includes hyperdiploidy (with >50 chromosomes), 
and two translocations in B-progenitor ALL t(12;21)(p13;q22) encoding ETV6-RUNX1 and 
t(1;19)(q23;p13.3) encoding TCF3-PBX1. In the other hand, hypodiploidy (<44 
chromosomes), translocations in B-progenitor ALL (t(9;22)(q34;q11.2) and t(17;19) 
encoding BCR-ABL (Philadelphia chromosome) and TCF3-HLF respectively, 
immunoglobulin heavy chain locus (IGH) and mixed lineage leukemia gene (MLL) 
rearrangements are associated with poor outcome.11, 12 
 
 
 
 
 
 
 
 
 
Figure 2 – Genetic alterations of pediatric ALL. The risk stratification is based on these 
genetic aberrations (adapted from Mullighan, 2013 
11
).  
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1.2.3 In vivo treatment response 
Each patient has a different blast cell reduction in the peripheral blood (PB) or bone 
marrow (BM) after exposure to several anti-leukemic agents. Basically, the less time that 
is needed for reduction, the more sensitive is the patient to that treatment. The detection 
of MRD has considered to be the most powerful diagnostic tool in the contemporary ALL 
treatments since it allows monitoring in vivo response to treatment.13 
Different informative checkpoints have been established in the treatment protocols 
and predefined MRD levels at these checkpoints can predict the risk of relapse. Patients 
with negative MRD (minimum sensitivity of 10-4) on treatment day 33 (TP1, after remission 
induction therapy) and day 78 (TP2, after consolidation therapy) are considered standard 
risk (SR). Patients with positive MRD detection at either one or both time points but with 
levels <10-3 at TP2 are classified as intermediate risk (IR). Finally, when high levels of 
MRD (≥10-3) are detected in the TP2, patients are stratified as high risk (HR).14 
The MRD levels can be assessed by two different techniques: flow cytometry analysis 
of the aberrant expression of leukemia specific antigens or quantitative RT-PCR detection 
of leukemia specific immunoglobulin (Ig) and T-cell receptor (TCR) gene rearrangements 
or fusion transcripts. However, the sensitivity, applicability, time and cost are different for 
these techniques.13 
 
 
Favorable outcome Unfavorable outcome 
Clinical 
factors 
 Age: 1-9 years old 
 Leukocyte count < 5 x 10
9
/L 
 B-ALL 
 Age: < 1 or > 10 years old 
 Leukocyte count > 50 x 10
9
/L 
 T-ALL 
Cytogenetic 
abnormalities 
 High hyperdiploidy 
(51-65 chromosomes) 
 t(12;21) encoding ETV6-RUNX1 
 t(1;19) encoding TCF3-PBX1 
 Hypodiploidy (less than 44 
chromosomes) 
 t(17;19) encoding TCF3-HLF 
 t(9;22) encoding BCR-ABL 
(Philadelphia chromosome) 
 MLL gene rearrangement at 11q23 
 IGH translocations 
Minimal residual 
disease 
 Standard risk patients: negative 
MRD (≤10
-4
) at day 33 and 78 of 
treatment 
 Intermediate risk patients: MRD level 
<10
-3 
at day 78 of treatment 
 High risk patients: MRD level ≥10
-3
 at 
day 78 of treatment 
Table 1 – Factors used for pediatric ALL risk stratification. 
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1.3 Characterization of the t(1;19) and t(17;19) ALL translocations 
TCF3 gene (also termed E2A in the past) encodes transcription factors (E12, E47 and 
E2-5) that function as specific regulatory elements in target-gene promoter or enhancer 
regions and are essential for normal lymphopoeisis, especially for B-cell development.15 
Chromosomal translocations generally create a fusion gene that encodes for a 
chimeric protein with novel structural and functional properties. TCF3 proteins can be 
converted into oncogenic transcription factors and two distinct translocations associated 
with TCF3 are found in pediatric ALL: t(1;19)(q23;p13) and t(17;19)(q21-q22;p13) that 
encode for TCF3-PBX1 and TCF3-HLF respectively (Figure 3). The t(1;19) translocation 
generates a chimeric transcription factor which results from the fusion of the N-terminal 
transactivation domains of TCF3 with the C-terminal and homeodomain of PBX1. In 
another hand, the fusion protein that results from the t(17;19) translocation contains also 
the N-terminal transactivation domains of TCF3 but it is fused with the C-terminal and the 
basic leucine zipper (bZIP) regions of HLF, a member of the PAR family transcription 
factors.15, 16 
Since both translocations are derived from the translocation involving TCF3 but 
associate with opposite clinical outcome (TCF3-PBX1 is associated with good outcome 
and the TCF3-HLF is not curable at the moment), they represent a good model to study 
the pathogenesis of TCF3 translocation associated ALL. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 – Two TCF3 translocations in ALL that originate chimeric proteins.  
(A) t(1;19)(q23;p13) encodes TCF3-PBX1 and (B) t(17;19)(q21-22;p13) encodes TCF3-HLF. 
AD1/AD2 – transcriptional activation domains; bHLH – basic helix loop helix; HD – 
homeodomain;PAR – proline and acidic amino acid rich domain; bZIP – basic leucine zipper 
(adapted from Hunger, 1996 
15
)  
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1.4 VNN2 
1.4.1 Characterization of VNN2 and its function 
Vanin-2 (VNN2), also known as GPI-80, is a human glycosylphosphatidylinositol 
(GPI)-anchored cell-surface protein. It is a member of the vanin (vascular non 
inflammatory molecule) family which expression has been demonstrated in colon, spleen, 
placenta, lung and leukocytes.17 
The function of VNN2 is not well-characterized widely. In neutrophils, VNN2 is 
expressed on the surface membrane of the cells and is intracellular stored in secretory 
vesicles as a soluble form (without GPI-anchor).18 VNN2 is involved in the neutrophil 
adherence and transendothelial migration processes.19 It seems that it has a physical 
interaction with β2-integrin Mac-1 20. When adhesion to endothelial cells happens, VNN2 
may dissociate from the Mac-1 and move to the pseudopodia of the neutrophil. 
Conversely, the chemotaxis leads to the release of VNN2 that is stored in the internal 
vesicles.17 
In a recent study, Prashad and colleagues proved the expression of VNN2 in the 
human fetal liver, defining a population of cells with hematopoietic stem progenitor cells 
property with self-renewal ability. These cells were able to migrate between fetal 
hematopoietic sites and the function relies on the colocalization of VNN2 and ITGAM on 
the cell surface.21 
1.4.2 VNN2 clinical significance in pediatric ALL 
Previously, in our group, a cell surface glycoproteomics profile has been performed in 
ALL patients‟ samples in order to identify cell surface markers that may be characteristic 
for resistant disease. The surface proteomes of 19 B-cell-precursor-ALL (BCP-ALL) 
patient-derived xenografts including 8 very high risk patients and 11 standard risk patients 
with an excellent clinical outcome were defined in our previous studies using the Cell 
Surface Capturing (CSC) technology25. With this method, 13 proteins that were detected 
preferentially in VHR-ALL were selected (Figure 4), most of them being involved on cell 
adhesion and migration (VNN2, VNN1, ITGAM, CD33, CD302 and CEAM1). Specially, 
VNN2 was only found in VHR ALL patients (4 of 8) and ITGAM was co-expressed in 3 of 
them. The co-expression of these two genes has recently been described as important for 
self-renewal of human fetal hematopoietic stem cells, whereby RNA interference with 
VNN2 or ITGAM both impaired survival in vitro and engraftment/hematopoietic 
reconstitution ability in xenografts.21 One of the 4 VNN2 positive patients was also a 
TCF3-HLF positive case, leading our group to focus on this protein. 
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Figure 4 – Surface proteome of 19 BCP-ALL cases. 8 VHR and 11 SR BCP-ALL cases are 
compared. 
On a second step, a cohort of 663 pediatric ALL patients from the clinical study ALL-
BFM-200 was analyzed retrospectively by our group in order to prove that high VNN2 
expression correlates with high risk disease and relapse. Quantitative PCR was 
performed in 209 SR-ALL, 345 IR-ALL and 109 HR-ALL cases (Figure 5). Very high levels 
of VNN2 transcripts were mostly identified in IR and HR ALL. Moreover, the expression 
levels were significantly higher in IR-ALL (1,076 ± 0.1522, p-value 0.0073) and HR (2,502 
± 0.6765,  p-value 0,0001) patients compared to SR-ALL (0,5409 ± 0.0444). To further 
explore the relevance of this data, univariate Cox model was used and a threshold value 
for VNN2 expression was established which corresponds to a normalized delta CT value 
of 1.13 (Figure 5, dashed line). Using this threshold, 57% of HR-ALL, 27% of IR ALL and 
12% of SR-ALL were defined as positive, suggesting that high VNN2 expression is 
associated with high risk disease. 
 
 
 
 
 
 
 
 
 
Figure 5 – VNN2 mRNA expression of 663 ALL patients. SR (n=209), IR (n=345) and HR 
(n=109). VNN2 mRNA is presented as logarithmic value of 2
-ΔΔCt
 (ΔCt=CtVNN2-CtSDHA) 
normalized for a reference sample with lowest VNN2 expression. The VNN2 expression threshold 
relative to this cohort is 1.13 (black dashed line). 
  
    
 
18  
 
The median event-free survival (EVS) probability of VNN2-high ALL was significantly 
lower than the rest of this cohort (Figure 6a). When comparing with each subgroup, 
significant effects were observed in IR-ALL (Figure 6b) and in SR group (Figure 6c) while 
in HR-ALL, VNN2-high cases did not further predict relapse than the remainder of the HR 
patients in this cohort (Figure 6d). Since the HR-ALL group receives more intensive post-
induction chemotherapy, it is possible that treatment intensification may not provide a 
survival advantage in this subgroup of patients. 
 6 – Event Free Survival analysis (EFS) of the different risk groups based on VNN2 
threshold (1.13) predictive of higher risk of relapse. EFS of VNN2-high ALL vs. EFS from rest 
of the cohort (a), EFS of VNN2-high vs. EFS from rest of the SR subgroup (b), EFS of VNN2-high 
vs. EFS from rest of the IR subgroup (c) and EFS of VNN2-high vs. EFS from rest of the HR 
subgroup (d).  
 
Furthermore, another retrospective experiment was undertaken to explore if VNN2 
detection by flow cytometry could provide a more strict identification of ALL cases at risk. 
Cases positively detected by flow cytometry and qRT-PCR for VNN2 where selected and 
their EFS was compared to the group of patients in the same cohort that was defined as 
VNN2 negative (Figure 7). A significant difference was observed as 50% of the VNN2 
positive cases have relapsed.  
 
 
b a 
c d 
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Figure 7 – Event Free Survival analysis (EFS) based on flow cytometry and qRT-PCR 
VNN2 expression assessment. 
Surface expression of VNN2 could be a potential prognostic indicator that identifies 
TCF3-HLF positive ALL as well as a fraction of cases with high risk of relapse. Detecting 
its expression at diagnosis, could distinguish some of relapse cases that are currently 
considered as IR. With treatment adjustment, the survival probability of these cases could 
be improved. 
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2. Aims of the thesis 
Regarding the fact that VNN2 is highly expressed in IR and HR ALL patients, 
especially on the TCF3-HLF cases, the principal aims of the present thesis were: 
 To investigate the functional role of VNN2 in pediatric ALL; 
Using the cutting-edge CRISPR/Cas9 technique to knockout VNN2 in ALL cell lines 
and patients‟ samples to investigate if VNN2 play a role on the leukemia cells homing and 
engraftment.  
 To validate a VNN2 antibody for diagnosis; 
To compare the sensitivity and specificity of a new commercially available VNN2 
antibody (clone 04) with another one (clone 3H9) that was described in most of the 
studies done up to date. For that, a cell line overexpressing VNN2 was generated and the 
antibody‟s performance was tested by FACS. The new antibody was also validated on 
patient-derived xenograft samples through the comparison between both with flow 
cytometry.  
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3. Materials and methods 
 
3.1 Cell culture 
Human Embryonic Kidney 293T cells (HEK 293T; DSMZ) were cultured in Dulbecco‟s 
modified eagle‟s medium (DMEM; Sigma® Life Science) supplemented with 10% Fetal 
Bovine Serum (FBS; Sigma® Life Science), L-Glutamine (2 mM; AMIMED) and Penicillin 
Streptomycin (P/S; 100 IU/ml; Gibco® by Life Technologies). The cells were detached from 
the bottom before splitting using Trypsin-EDTA PBS 1:250 (AMIMED). 
The cell lines 658 (E2A-HLF positive; generated by B. Marovca in our group by 
cultivating xenograft patient material (patient ID: L707)) and Nalm6 (t(5;12); DSMZ) were 
maintained in RPMI-1640 medium (Sigma® Life Science) supplemented with 10% heat-
inactivated (h.i.) FBS, L-Glutamine (2mM) and P/S (100 IU/mL). 
All cultured cells were kept in the incubator at 37°C, 5% CO2. Cells were thawed by 
putting them for 1 minute into a 37°C water bath followed by gentle addition of RPMI-1640 
medium 10% FBS. To freeze the cells, h.i. FBS with 10% dimethyl sulfoxide (DMSO, 
Sigma® Life Science) was used as freeze medium and subsequently the cells were stored 
at -80°C. 
3.2 CRISPR/Cas9 nuclease RNA-guided knockout of VNN2 
The CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9 system 
is a recently emerged technique for genome editing adapted from type II prokaryotic 
CRISPR immune system. The use of a single-guide RNA (sgRNA) associated with Cas9 
nuclease allows the introduction of DNA-double strand breaks (DSB) at specific genomic 
sites. The sgRNA contains 20 nucleotide guide sequence that can be designed to target a 
specific gene. The only requirement for the selection of Cas9 target sites is the presence 
of a protospacer-adjacent motif (PAM) immediately downstream of the target site (5‟-
NGG). Targeted cleavage of the genome by Cas9 may lead to loss-of-function mutations 
since sgRNA targets to coding regions of genes and, consequently, can create frame shift 
insertion/deletion (indel) mutations.22 Simultaneous lentiviral delivery of Cas9 and sgRNA 
throughout a single vector enables application of this technique in almost any cell type of 
interest, without the need to first generate cell lines that express Cas9.23 
3.2.1 Targeting sites selection 
Genome sequence of VNN2 (Gene database from NCBI) was analyzed by 
http://crispr.mit.edu to design a suitable targeting sequence for sgRNA. Then, the best 
sequence was chosen and used to create the forward primers. At the 5‟ prime site of the 
forward and reverse primer the sequences CACCG and AAAC were added respectively 
  
    
 
22  
 
for cloning into LentiCRISPR-GFP vector (from Feng Zhang Lab). Primers were ordered 
from Microsynth. 
  
Name Primers 
VNN2-F1 
VNN2-R1 
CACCGTACCAACCTGCAGGGTTATT 
 
AAACAATAACCCTGCAGGTTGGTAC 
VNN2-F2 
VNN2-R2 
CACCGACGGAATCCAGTTCACCTGA 
 
AAACTCAGGTGAACTGGATTCCGTC 
VNN2-F3 
VNN2-R3 
CACCGGTGGAGTCACGGGAATTACA 
 
AAACTGTAATTCCCGTGACTCCACC 
VNN2-F4 
VNN2-R4 
CACCGGTGACTTTCAACACCGCATT 
 
 
AAACAATGCGGTGTTGAAAGTCACC 
VNN2-F5 
VNN2-R5 
CACCGTTGGGTAGGCAAGCGAGGAT 
 
 
AAACATCCTCGCTTGCCTACCCAAC 
 
Table 2 – Primers selected for lentiviral CRISPR targeted VNN2 knockout. 
 
3.2.2 Plasmid construction 
Lyophilized oligo primers were diluted with H2O to a final concentration of 100 μM. To 
anneal the single stranded primer pairs, 10 μL forward and reverse primers were mixed 
with 10 μL NEB Tango buffer (Thermo Scientific) and 70 μL H2O per each primer pair. To 
anneal the oligo the samples were heated up to 95°C and kept for 5 minutes at this 
temperature. After the samples had reached room temperature, annealed double-
stranded oligos were cloning into linearized lentiCRISPR-GFP plasmid by T4 DNA ligase 
(Thermo Scientific). 
3.2.3 Transformation of chemical competent bacteria  
5µL of ligation product from the step before was added to 50 μL chemical-competent 
bacteria E.coli DH5 alpha (Invitrogen). After 2 minutes on ice, the samples were heat 
shocked for 100 seconds at 42°C and then put back on ice. 200 μL of S.O.C medium 
(Sigma® Life Science) was added to each sample before incubation for 1 hour at 37°C 
with a minimum shake of 300 rpm. Subsequently, the bacterial suspensions were seeded 
on LB agar Amp+ Petri dishes and incubated at 37°C overnight.  
3.2.4 Colony PCR for identification of plasmid of interest 
From each plate, three colonies were picked to check oligo insertion using PCR. The 
colonies were pricked with a 20µL pipetting tip and added in PCR solution (0,5µL U6 
forward primer, 0,5µL specific oligo reverse primer, 5µL ReadyMix™ Taq PCR Reaction 
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Mix (Sigma-Aldrich®) and 4µL water. Next, the following program was run: 1 cycle of 3 
minutes at 95°C, 25 cycles of 30 seconds at 95°C, 30 seconds at 55°C and 10 seconds at 
72°C and an additional cycle of 10 minutes at 72°C. 
3.2.5 Amplification of transformed bacteria 
One positive clone per each condition was chosen to amplify for DNA extraction. 
Colonies were picked by pricking them with a 20 μL pipetting tip and dropping the tip in a 
15 mL Falcon tube filled with 5 mL of LB-medium Amp+. The bacteria were incubated at 
37°C overnight with shaking at 225 rpm (Certomat® BS-T, Sartorius).  
3.2.6 Plasmid DNA extraction 
DNA extraction was performed using QIAprep Spin Miniprep Kit (Qiagen). DNA 
concentrations were measured by Nanodrop® (ND-1000 Spectrophotometer, witec ag). 
3.2.7 Virus production 
For transfection, HEK 293T cells were plated at T75 cm2 cell culture flask in 13 mL 
DMEM medium 10% FBS h.i., L-Glutamine (2 mM) and P/S (100 IU/ml) and let to reach 
60 – 80% of confluence. 
For second-generation packaging, the psPAX2 packaging vector (Addgene) was 
used. The transfection mix was prepared as follows: 30 μg transfer plasmid (plasmid of 
interest), 11,25 μg psPAX2 (packaging plasmid), 11,25 μg pVSV-G (capsid plasmid), 1,5 
ml DMEM medium and 112,5 μl PEI “Max” (Cat-Nr:24765-2, Polysciences). After 5 
seconds of vortexing and 20 minutes at room temperature, the entire mixture was added 
dropwise to the flask. After 4 hours at 37° C, 5% CO2, the medium was aspirated and 13 
ml of new DMEM medium completed with 10% FBS h.i., L-Glutamine (2 mM) and P/S 
(100 IU/ml) was added per plate. After additional 24 and 48 hours, the supernatant was 
collected and 13 ml of fresh medium added to the plate. Supernatants were passed 
through a 0.45 μm millipore filter (TPP®) and centrifuged for 3 hours at 25000g. Next, 
supernatants were discarded, virus ressuspended in 1mL of RPMI-1640 complete 
medium and were ready to do the transduction. 
 
3.2.8 Nalm6 and 658 cell lines transduction 
500‟000 cells of each cell line were suspended in 500 µL virus and 0,5 µL polybrene 
(8ug/ul) in a 24 well-plate. After 24 and 48 hours, the medium was replaced by fresh 
medium and cells were considered free of virus.  
3.3 pINDUCER lentiviral system for VNN2 overexpression 
A third-generation inducible cDNA expression lentiviral system (pINDUCER21) from 
Stephen Elledge (Meerbrey et al Proc Natl Acad Sci U S A. 2011 Mar 1;108(9):3665-70) 
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was used in order to inducible overexpress VNN2. This system is a single-vector system 
where the transcription is activated after addition of doxycycline (dox).24 
3.3.1 Primer selection for VNN2 overexpression plasmid construction 
Nucleotide database from NCBI was used to see the coding sequence (CDS) of 
VNN2. The mRNA transcript variant 1 from homo sapiens VNN2 was used. For the 
forward sequence, 25 nucleotides starting with the start codon were chosen. Immediately 
5‟ to this sequence, 15 nucleotides homolog to the vector including a SpeI restriction site 
and an ACC sequence were added from cloning. The reverse sequence included 24 
nucleotides with the stop codon and was followed at 3‟ by 15 nucleotides that were 
homologs to the vector and included the BstbI restriction enzyme. Primers were ordered 
from MicroSynth. 
 
VNN2 Primers 
Forward 
GCGGCCCCGA  ACTAGT ACC ATGGTCACTTCCTCTTTTCCAATCT 
Homolog sequence    SpeI 
Reverse 
GATCATAGCTTTGCAAAATATTGTAATGTTATAG TTCGAA TACCCATACGA 
BstbI  Homolog sequence 
 
Table 3 – Primers selected for lentiviral pINDUCER21-VNN2 overexpression. 
 
3.3.2 Plasmid construction 
Lyophilized oligo primers were diluted with H2O to a final concentration of 50 μM. The 
vector pcDNA3.1(+) (Invitrogen) containing the VNN2 cDNA was used as a template (10 
ng/μL) in the following PCR reaction: 0,5 μL forward and reverse primers were mixed with 
10 μL 5x GC buffer, 1,5 μL DMSO, 1 μL dNTPs, 1 μL pcDNA3.1-VNN2, 0,5 μL Phusion® 
High-Fidelity DNA Polymerase (Life Technologies) and brought to a final volume of 50 μL 
with H2O. Next, the following program was run: 1 cycle of 30 seconds at 98°C, 30 cycles 
of 10 seconds at 98°C, 30 seconds at 55°C and 2 minutes at 72°C and an additional cycle 
of 5 minutes at 72°C. 
To obtain the PCR amplified VNN2, an agarose gel electrophoresis was run and the 
band corresponding to VNN2 was extracted using Gel Extraction Kit QIAquick (Qiagen). 
Subsequently, the PCR product was digested with  BcuI and BstbI restriction enzymes 
(Thermo Scientific) at 37°C overnight: 2,5 μL from each restriction enzyme, 5 μL 10x NEB 
Tango buffer, 2,5 μg (maximum) of VNN2 cDNA and H2O to a final volume of 50 μL. To 
clone VNN2 into the pINDUCER21 vector, a ligation reaction was prepared: 1 μL VNN2 
cDNA, 1,5 μL linearized vector, 1 μL NEB T4 ligase buffer, 1 μL of T4 DNA ligase 
(0,5W/µL) and H2O to a final volume of 10 μL. The sample was left for 1 hour at room 
temperature. 
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3.3.3 Transformation of chemical competent bacteria, amplification of 
transformed bacteria and plasmid DNA extraction 
These 3 steps were done as described before. The exception is that here when we 
pick the colonies to amplify, we don‟t know which one is well constructed. It is only 
possible to confirm on a later step. 
3.4.4 Digestion validation 
Another digestion was done for each colony amplified in order to confirm the well 
construction of the plasmid. 2,5 µL SalI restriction enzyme (Thermo Scientific), 5 µL 10x 
NEB Tango buffer, 0,5 µg pINDUCER21-VNN2 were brought to a final volume of 50 µL 
with H2O. The reaction was let to occur during 4 hours at 37°C. 
3.4.5 Virus production 
For transfection, HEK 293T cells were plated in 6 well-plate with 2 mL DMEM medium 
10% FBS h.i., L-Glutamine (2 mM) and P/S (100 IU/ml) and let to reach 60 – 80% of 
confluence. 
For second-generation packaging, the psPAX2 packaging vector was used. The 
transfection mix was prepared as follows: 4 μg transfer plasmid (plasmid of interest), 1,5 
μg psPAX2 (packaging plasmid), 1,5 μg pVSV-G (capsid plasmid), 200 µL DMEM medium 
and 15 μl PEI. After 5 seconds of vortexing and 20 minutes at room temperature, the 
entire mixture was added dropwise to the well. After 4 hours at 37°C, 5% CO2, the 
medium was aspirated and 2 ml of new DMEM medium completed with 10% FBS h.i., L-
Glutamine (2 mM) and P/S (100 IU/ml) was added. After 48 hours, the supernatant was 
collected, centrifuged for 5 minutes at 650 rpm and was ready to do the transduction. 
3.4.6 Nalm6 cell line transduction 
Transduction was performed as described before. 
 
3.5 Flow cytometry analysis and cell sorting 
Flow cytometry analyses were performed using BD FACS Canto™ II (BD 
Biosciences). 
BD FACS Aria™ III (BD Biosciences) was used for cell sorting. 
3.6 658 VNN2 knockout efficiency 
658 transduced cells were rinsed with 1x PBS and incubated with 5 μg/mL of mouse 
IgG1 anti-human GPI-80 (clone 3H9, PE conjugated, MBL® International Corporation) for 
20 minutes at 4ºC. After incubation, the cells were rinsed again with 1x PBS and VNN2 
expression was measured by FACS. 
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3.7 Nalm6 VNN2 overexpression efficiency 
Nalm6 transduced cells were treated with 0, 10, 100 or 1000 ng/mL doxycycline for 3 
days. After dox treatment, cells were incubated with 5 μg/mL of mouse IgG1 anti-human 
GPI-80 (clone 04, PE conjugated, Sino Biological Inc.) for 20 minutes at 4ºC. After 
incubation, the cells were rinsed again with 1x PBS and VNN2 expression was measured 
by FACS. 
3.8 VNN2 expression in patient-derived xenografts 
Patient-derived xenograft samples were stained with mouse IgG1 anti-human-GPI-80 
(PE conjugated, clones 3H9 and 04) using different concentrations of 1,25, 2,5, 5 and 10 
μg/mL for 20 minutes at 4ºC. The same treatment procedure was applied for the isotype 
control (mouse IgG1, PE conjugated, abcam®). After incubation, the cells were rinsed with 
1x PBS and measured by FACS. 
3.9 Immunophenotyping 
Following antibodies were used for immunophenotyping of xenoamplified human ALL 
cells: mouse anti-human CD10 (APC conjugate, Clone HI10a, Cat No 312210, 
BioLegend, Frederick, USA), mouse anti-human CD19 (PeCy7 conjugate, Clone SJ25C1, 
REF 25-0198-42, eBioscience Inc., San Diego, CA, USA), mouse anti-human CD14 
(APCH7 conjugate), mouse anti-human CD34 (PerCpCy5 conjugate, REF 347222, BD 
Biosciences, San Jose, CA, USA), mouse anti-human CD2 (FITC conjugate) mouse anti-
human CD45 (Pacific Orange conjugate, REF MHCD4530, Invitrogen, Frederick, USA). 
For VNN2 detection the mouse IgG1 anti-human GPI-80 antibody (PE conjugate, clone 
3H9 or 04) was used. For compensation the following compensation beads were used: 
BD™ CompBeads Anti-Mouse Ig, κ (Cat No 51-90-9001229; BD Biosciences, San Jose, 
CA, USA). 
The Mean Fluorescence Intensity change (Delta MFI) was calculated as the 
difference between MFI values of populations stained with the monoclonal antibody of 
interest and the fluorescence minus one control (FMO). 
3.10 Computational analysis 
Flow cytometry results were analyzed with the software FACSDiva (Becton 
Dickinson) and FlowJo (version 10, TreeStar).  
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4. Results 
 
4.1 Overexpression of VNN2 by pINDUCER21 in ALL cells 
To test the sensitivity and specificity of a new commercial available antibody for 
VNN2 (clone 04), a DOX-inducible VNN2 overexpression plasmid was transduced to 
nalm6 cells. After 3 days treatment of increasing concentration of DOX, the expression 
level of VNN2 on cell membrane was measured by flow cytometry after staining with PE 
conjugated VNN2 antibody (clone4) (Figure 8). As shown in the figure, without DOX 
treatment (0 ng/ml), transduction of pINDUCER21-VNN2 plasmid does not change VNN2 
levels per se (from 1,61% to 3,89%). However, after DOX treatment, the transduced cells 
remarkably increased VNN2 expression level in a dose-dependent manner. Thus, the new 
VNN2 antibody (clone 04) was able to detect increase level of VNN2. 
 
 
 
Figure 8 – pINDUCER21-VNN2 overexpression in nalm6 cell line. No transduced cells 
used as a control for gating the VNN2 basal levels. Increased dox concentrations were used to 
overexpress VNN2 in the transduced cells.  
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4.2 Validation of  VNN2 expression in patient-derived xenografts 
The VNN2 expression in two patient-derived xenograft samples, A11 (TCF3-HLF 
positive case) and G63 (TCF3-PBX1 positive case), was measured by two commercial 
available antibodies (clones 3H9 and 04). Increasing concentrations of antibodies were 
used for this titration analysis (Figure 9). For A11, the signal intensity increased as 
increasing concentrations of antibody 04 were used. Antibody 3H9 reaches the saturation 
at concentration of 2,5 µg/mL in this case. However, at concentration of 10 µg/mL, the 
isotype control starts to show a considerable background suggesting that this 
concentration is too high to use. In the same setting, no VNN2 signal was detected in the 
G63 patient.  
.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Figure 9 – VNN2 expression in a TCF3-HLF and TCF3-PBX1 positive cases. VNN2 
expression was validated with two anti-VNN2 antibodies (clone 3H9 and 04).   
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Next, the VNN2 expression in six TCF3-HLF positive ALL patients was tested by 
these two VNN2 antibodies at concentration of 5 µg/mL. As shown in figure 10, delta 
VNN2 MFI (VNN2 expression – FMO) for each antibody demonstrates that they detected 
VNN2 levels in all the patients. The signal intensity from 3H9 was higher than 04, 
suggesting 3H9 is more sensitive in this setting. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10 – VNN2 expression in 6 TCF3-HLF positive ALL patients. VNN2 expression was 
validated with two anti-VNN2 antibodies (clone 3H9 and 04).  
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4.3 Knockout of VNN2 by CRISPR/Cas9 in ALL cells 
Three weeks after transduction of VNN2 knockout plasmid (CRISPR-VNN2), the cell 
membrane expression of VNN2 was measured by flow cytometry. After staining with PE 
conjugated VNN2 antibody, the VNN2 levels were compared between GFP- 
(untransduced) and GFP+ (transduced) populations. As shown in figure 11, the VNN2 
levels are not different between GFP- and GFP+ population in cells transduced with two 
CRISPR-scramble plasmids (no specific-targeting in genome) suggesting transduction of 
CRISPR plasmid does not change VNN2 level per se. However, all 5 of the VNN2-
targeting plasmid remarkably decrease the VNN2 level in transuded populations (GFP+). 
Importantly, comparing the ratio between PE- and PE+ within the GFP+ group, the sgRNA 
2 and 5 generated the first two high ratio suggesting that these two sequences are more 
potent to knockout VNN2 than the others. Thus, though the 658 cells only express 
moderate VNN2 on cell membrane, the remarkable decrease of VNN2 level in the cells 
transduced with CRISPR plasmid targeting VNN2 suggests the knockout works in this cell 
line. 
Another way to analyze the knockout efficiency is to gate the cell population in two 
groups (GFP- and GFP+) and compare the mean fluorescence intensity (MFI) of VNN2 of 
these two groups. As shown in Figure 12, the first panel indicate the basal level of VNN2 
(blue curve) against background (red curve) in 658 cells. The next two panels represent 
the negative controls (scrambles 1 and 2): the VNN2 MFI from the GFP+ population (pink 
curve) is quite similar to the one from the GFP- population (green curve) confirming that 
the VNN2 level has no change in transduced population. The next five panels represent 
the five different sgRNAs that target VNN2. It is obvious that the VNN2 level is decreased 
in all the GFP+ populations (pink curves). Again, within the five different constructions, the 
sequence number 2 is the most potent one.  
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Figure 11 – LentiCRISPR-VNN2 knockout in 658 cell line.  
No transduced and no stained cells (a), no transduced and stained cells with PE-VNN2 
antibody (b), lentiCRISPR scrambles 1 and 2 stained cells with PE-VNN2 antibody (c and d) and 
lentiCRISPR-VNN2 with five different targets cells stained  with PE-VNN2 antibody (e, f, g, h and i). 
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Figure 12 – LentiCRISPR-VNN2 knockout in 658 cell line. No transduced and no stained 
(red curve) vs. no transduced and stained (blue curve) cells with PE-VNN2 antibody (3H9).  GFP
-
 
(green curve) vs. GFP
+ 
(pink curve) cells from transduced populations (lentiCRISPR) stained with 
PE-VNN2 antibody. 
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5. Discussion 
5.1 VNN2 expression is associated with high risk disease and relapse in ALL 
Through a surfaceome analysis of ALL patients belonging to different prognostic 
groups (SR, IR and HR), VNN2 was mostly identified in patients that are categorized as 
high levels of MRD disease after induction chemotherapy treatment (an indication of 
resistance to therapy). Within these, all the patients carrying the translocation t(17;19) 
(TCF3-HLF) have high levels of VNN2. The chimeric protein resulted from TCF3 and HLF 
gene rearrangement defines a subtype of ALL that is typically associated with relapse and 
poor outcome. Currently, this translocation is the only one that VNN2 is exclusively 
associated with. Thus, the detection of VNN2 by flow cytometry will provide a convenient 
and cost effective approach to select ALL cases for specific genetic testing of the TCF3-
HLF translocation.  
To further clarify this relationship between VNN2 expression and relapse, a 
retrospective analysis involving more than 600 pediatric ALL patients was performed. An 
enrichment of cases with high levels of VNN2 RNA expression was found in patients with 
intermediate risk and high risk of relapse. It was also possible to set a threshold of VNN2 
expression level that distinguishes a subclass of patients with significantly higher risk of 
relapse. With this threshold, the EFS of VNN2-high cases from each group (SR, IR and 
HR) was compared with the EFS from the remaining patients from the respective group 
showing a tendency of relapse for that patients. Interestingly, the identification of patients 
in the IR group that predict relapse is of high interest since they could be subjected to 
more intensify treatments at the first place. This would change the fact that IR still 
constitutes the group with the largest number of relapses in ALL but for which currently no 
alternative markers are available. The detection of VNN2 by flow cytometry also 
demonstrated that 50% of patients with high levels of VNN2 will relapse. This data 
indicates that including of VNN2 in diagnostic flow procedures could contribute in 
identifying more potential high risk cases. 
In this way, the risk stratification tools should include VNN2 surface expression as 
well as the genomic information and the MRD assessment in the future. These data 
provided the basis for an ongoing prospective evaluation of this biomarker on the 
international AIEOP-BFM-ALL-2009 trial including Switzerland, Germany, Italy and 
Austria. The inclusion of VNN2 in the diagnostic immunophenotyping panel of the study 
will serve to identify more effectively the TCF3-HLF positive cases that need alternative 
experimental therapies.  
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5.2 VNN2 antibody (clone 04) validation for diagnosis 
In the present study, a new commercial available VNN2 antibody (clone 04) has been 
tested and compared with an old one that was being used before (clone 3H9). Clone 04 is 
produced from a recombinant human VNN2 while the 3H9 comes from human activated 
neutrophils. Neverthless, both of these antibodies recognize the peptide portion from the 
VNN2 surface membrane protein. 
Through the establishment of a VNN2 inducible overexpression system and the use of 
different concentrations of dox to induce the protein expression, it is confirmed that the 
signal detected from the 04 antibody is regarded to VNN2. Thus, it makes it a rival of the 
3H9. To clarify which one is more sensitive, both antibodies were tested at different 
concentrations on two patient-derived xenografts with opposite outcome (TCF3-HLF and 
TCF3-PBX1). With increasing concentration of both antibodies, it is evident that 3H9 
reaches the saturation condition faster than clone 04. However, at concentration of 5 
µg/mL, their behavior is similar. To further clarify this, 6 TCF3-HLF positive ALL cases 
were incubated with both antibodies at the same concentration (5 µg/mL). 3H9 presented 
more sensitive signal in 4 of the 6 patients. If each antibody recognizes different epitope 
from VNN2 and these are not equally distributed on the surface membrane from the cells, 
this could be an explanation for the differences observed. Nevertheless, 04 clone is also a 
good candidate. 
5.3 A potential role of VNN2 on homing and engraftment of ALL  
Explore the functional role of VNN2 expression in IR and HR ALL cases is one of the 
principle goals of this project. A VNN2 knockout approach was established and validated 
in ALL cells using the lentiviral CRISPR/Cas9 strategy. To have a high chance to obtain 
an effect, five sgRNAs targeting VNN2 (5 different exon of) were designed. All of them 
remarkably decrease VNN2 levels on a TCF3-HLF cell line (658). However, we are still far 
away to see a potential relationship as it was proposed.  CRISPR is a cutting-edge 
genome-editing technique that can be employed to introduce a specific point mutation or 
correct a pre-existing mutation. The advantage of this system is that a completely 
eliminating gene function can be achieved, making it possible to study phenotypes that 
require a complete loss of gene function.26, 27 Since VNN2 is involved on migration and 
adhesion of neutrophils19, we expect a potential function of VNN2 on the engraftment 
and/or homing capacity of ALL cells. The establishment of a TCF3-HLF VNN2 knockout 
cell line was the first step of this loss-of-function study. Confirmation studies are still 
required for these preliminary data. It is still needed to enrich or purify the knockout 
population by sorting the cells of interest and then test their efficiency in another way (eg. 
western blot). Alternatively, deep-sequence could be done to check and quantify the 
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genomic sequence edited by CRISPR/Cas9 system. After confirmed the knockouts, the 
next step is to delete VNN2 in patient-derived samples and investigate the biological effect 
in vivo. The idea is to transplant VNN2 knockout cells into NSG mice and track if VNN2 
knockout will change the behavior of these cells in vivo including homing and/or 
engraftment. Recently, Prashad and colleagues21 have discovered that VNN2 
distinguishes a population of human fetal liver hematopoietic stem cells (HSCs) with self-
renew ability. Through the transplantation of VNN2+ or VNN2- HSCs cells into NSG mice, 
they found that only the VNN2+ HSCs had the capacity to engraft and self-renew after 
transplantation. They also observed that VNN2 colocalizes with ITGAM (as already 
described by Huang and colleagues20) and confirmed that both are necessary for the 
maintenance of HSCs properties. Moreover, when they knocked down VNN2 or ITGAM, 
transduced HSCs were not able to engraft the bone marrow after transplantation into NSG 
mice suggesting that these two proteins work together and are required for maintaining 
HSCs function. Thus, if we could confirm a similar role of VNN2 on leukemia cells, VNN2 
could potential be a therapeutic target in the future. Scrutinizing the functional role of 
VNN2 in IR and HR ALL is ongoing. 
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6. Conclusion 
In conclusion, my Master Thesis contributed to the development of a VNN2 knockout 
TCF3-HLF cell line. These preliminary data constitute the basis for further in vivo 
investigation of the functional role of VNN2 in SR and HR ALL.  
A different monoclonal antibody for VNN2 was also validated through an 
overexpression system as well as in TCF3-HLF positive ALL patients. These two 
experiments have contributed as supplementary figures in a paper that will be submitted 
in the future: 
 
Vanin-2 (GPI-80) identifies aggressive subtypes of childhood acute lymphoblastic 
leukemia 
Anna Rinaldi1, Nastassja Scheidegger1, Gunnar Cario2, Andreas Hofmann3, Paulina 
Mirkowska1, Elena Vendramini4, Martina Temperli1, Marco Giordan4, Andreia 
Guimarães1, Cornelia Eckert5, Mecklenbräuker Astrid6, Andishe Attabashi6, Renate 
Panzer-Grümayer6, Maria Pamela Dobay8, Truus teKronnie4, Giuseppe Basso4, Martin 
Stanulla7, Martin Zimmermann7, Bernd Wollscheid2, Beat Bornhauser1 and Jean-Pierre 
Bourquin1 
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Abstract   
The glycophosphatidylinositol anchored surface protein Vanin-2 (VNN2, GPI-80), which 
has been implicated in leukocyte adherence and migration, identifies human fetal liver 
hematopoietic stem/ progenitor cells (HSPCs) with self-renewal ability and is required for 
their hematopoietic function. Comparing the cell surface glycoproteome of 19 acute 
lymphoblastic leukemia (ALL) samples, we identified VNN2 as a unique feature in patients 
with a very high risk of relapse by minimal residual disease. In a retrospective analysis of 
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663 patients on the ALL-BFM-2000 treatment protocol high VNN2 transcript levels were 
associated with decreased event free survival. We show in a subset of this cohort that 
VNN2 detection by flow cytometry may serve as a prognostic marker instead. Furthermore 
all of 12 TCF3-HLF-positive ALL, which defines a currently incurable ALL subtype, were 
strongly surface VNN2, providing a simple procedure to preselect samples for specific 
diagnostic testing. VNN2 expression was not associated with other cytogenetic and copy 
number abnormality.  Antibody interference with VNN2 resulted in delayed homing of ALL 
to the bone marrow of immunodeficient mice, suggesting a potential role of VNN2 in 
leukemia trafficking. Thus surface VNN2 expression identifies TCF3-HLF-positive ALL as 
well as subset of ALL with unfavorable biology that cannot be defined by other diagnostic 
features and warrants prospective clinical investigation.  
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